CTOs on the Move

Q32 Bio

www.q32bio.com

 
Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.q32bio.com
  • 830 Winter Street
    Waltham, MA USA 02451
  • Phone: 781.999.0232

Executives

Name Title Contact Details
Saul Fink
Chief Technology Officer Profile

Funding

Q32 Bio raised $46M on 05/27/2020
Q32 Bio raised $60M on 10/29/2020

Similar Companies

Adicet Bio

Adicet Bio, Inc. is a publicly held biotechnology company (Nasdaq: ACET) discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

Biomet Microfixation

Founded by Walter Lorenz more than thirty years ago, Biomet Microfixation manufactures a complete range of craniomaxillofacial products, including LactoSorb, the first completely resorbable fixation system available in the U.S. Other products include

Epitopix

Epitopix is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aastrom

We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.

Cerulean

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.